Results 121 to 130 of about 2,631,955 (205)

To be or low TMB (tumor mutational burden)

Translational Cancer Research
Falk, Markus, Tiemann, Markus, Ficker, Joachim H., Brueckl, Wolfgang M.   +3 more
openaire   +2 more sources

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer. [PDF]

JCO Precis Oncol
Coleman RL, Rocconi R, Monk BJ, Walter A, Stanbery L, Willoughby D, Nagel C, Wei Q, Wallraven G, Horvath S, Tang M, Rao D, Bognar E, Nemunaitis J.   +13 more
europepmc   +1 more source

Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results. [PDF]

NPJ Breast Cancer
Fanucci K, Rozenblit M, Quintanilha JCF, Graf RP, Fischbach N, Pelletier M, Sivapiragasam A, Kumar PA, Kallem M, Sokol ES, Sivakumar S, Pavlick DC, Ross JS, Lustberg M, Pusztai L.   +14 more
europepmc   +1 more source

Differences in tumor mutational burden assessment: a national ring trial [PDF]

Acta Oncologica
Christine Federspiel Secher, Christina Westmose Yde, Britt Elmedal Laursen, Estrid l Høgdall, Henriette Sylvain Thomsen, Tim Svenstrup Poulsen, Mads Sønderkær, Tina Kringelbach, Mads Malik Aagaard Jørgensen, Rikke Frydendahl Sick Olsen, Anja Elaine Sørensen, null Christian Baudet, null Magnús Halldór Gíslason, null Michael Knudsen, null Ida Kappel Buhl   +14 more
openaire   +3 more sources

Distinct genomic landscapes of mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancer depending on tumor mutation burden (TMB) levels. [PDF]

J Immunother Cancer
Wang J, Xiu J, Farrell AP, Battaglin F, Arai H, Yang Y, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall J, Lou E, Khushman M, Sohal DPS, Hall MJ, Liu T, Oberley MJ, Spetzler D, Lenz HJ.   +20 more
europepmc   +1 more source

PC06.03 Tumor Mutation Burden - PRO [PDF]

Journal of Thoracic Oncology, 2018
openaire   +1 more source

Machine learning-based models for tumor mutation burden prediction in gastrointestinal cancers: a systematic review and meta-analysis. [PDF]

Discov Oncol
Rahimi P, Atighi F, Rezaei B, Rezaee H, Abdelbaset M, Nazari F, Zarrehparvar Ghouchani Nezhad S, Moradi Kashkoli M, Ghaffarzadeh A, Taghavi F, Goudarzi P, Samavarchitehrani A, Marashi A, Esmaeili Y, Zhian Zargaran F, Shirdel A, Asadi Anar M, Mousavi S.   +17 more
europepmc   +1 more source

AlphaMissense pathogenicity scores predict response to immunotherapy and enhances the predictive capability of tumor mutation burden. [PDF]

Transl Oncol
Adeleke D, Fadaka AO, Sibuyi NRS, Klein A, Meyer M, Rahul G, Jansen R.   +6 more
europepmc   +1 more source

Cancer of Unknown Primary Most Suggestive of Colorectal Origin With Microsatellite Instability-high Status and High Tumor Mutation Burden Including NTRK Fusion. [PDF]

Cancer Diagn Progn
Sato H, Hiraki M, Shimonishi T, Takase Y, Komiya N, Nakashima C, Irie H, Akagi Y, Aragane N.   +8 more
europepmc   +1 more source

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment. [PDF]

Cancer Rep (Hoboken)
Kai Y, Ikezawa K, Kozumi K, Urabe M, Takada R, Kinomoto T, Masumoto T, Kawabata M, Kishimoto H, Hosokawa K, Mukai K, Nakabori T, Yamaguchi Y, Sugimoto N, Ohkawa K.   +14 more
europepmc   +1 more source